At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

An update from KDIGO, an independent organization that aims to improve the care of patients with kidney disease worldwide. A layered approach is recommended while caring for patients with diabetes and ...

Please provide your email address to receive an email when new articles are posted on . The Kidney Disease Improving Global Outcomes updated the clinical practice guidelines for treating patients with ...

In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...

Finerenone use for 6 months was safe and associated with a significant 25% decrease in albuminuria for adults with type 1 diabetes and chronic kidney disease, according to data presented in the ...

LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO ...

In a recent study published in Kidney International Reports, researchers investigated the effects of semaglutide (administered once weekly) on kidney disease outcomes and changes in KDIGO (short for ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a new ...

The impact of chronic kidney disease (CKD) on patients and the health care system in the United States is substantial and expected to increase with the expanding obesity-driven diabetes epidemic. 1 ...

WHIPPANY, N.J.--(BUSINESS WIRE)--The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone 1, were ...